Shanxi C&Y Pharmaceutical Group Co Ltd - Asset Resilience Ratio

Latest as of September 2020: 0.26%

Shanxi C&Y Pharmaceutical Group Co Ltd (300254) has an Asset Resilience Ratio of 0.26% as of September 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Shanxi C&Y Pharmaceutical Group Co Ltd current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥5.00 Million
≈ $731.66K USD Cash + Short-term Investments

Total Assets

CN¥1.91 Billion
≈ $279.34 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2013–2014)

This chart shows how Shanxi C&Y Pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 300254 total asset value.

Liquid Assets Composition Over Time

This chart breaks down Shanxi C&Y Pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of Shanxi C&Y Pharmaceutical Group Co Ltd to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥5.00 Million 0.26%
Total Liquid Assets CN¥5.00 Million 0.26%

Asset Resilience Insights

  • Limited Liquidity: Shanxi C&Y Pharmaceutical Group Co Ltd maintains only 0.26% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Shanxi C&Y Pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio

Compare Shanxi C&Y Pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Kamada
TA:KMDA
Drug Manufacturers - Specialty & Generic 0.00%
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Viatris Inc
NASDAQ:VTRS
Drug Manufacturers - Specialty & Generic 1.48%
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
Drug Manufacturers - Specialty & Generic 4.31%
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
Drug Manufacturers - Specialty & Generic 1.01%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Drug Manufacturers - Specialty & Generic 5.90%

Annual Asset Resilience Ratio for Shanxi C&Y Pharmaceutical Group Co Ltd (2013–2014)

The table below shows the annual Asset Resilience Ratio data for Shanxi C&Y Pharmaceutical Group Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2014-12-31 1.84% CN¥21.76 Million
≈ $3.18 Million
CN¥1.18 Billion
≈ $172.87 Million
+1.81pp
2013-12-31 0.04% CN¥388.94K
≈ $56.91K
CN¥1.09 Billion
≈ $159.56 Million
--
pp = percentage points

About Shanxi C&Y Pharmaceutical Group Co Ltd

SHE:300254 China Drug Manufacturers - Specialty & Generic
Market Cap
$324.81 Million
CN¥2.22 Billion CNY
Market Cap Rank
#14539 Global
#4342 in China
Share Price
CN¥8.63
Change (1 day)
+2.13%
52-Week Range
CN¥7.27 - CN¥14.68
All Time High
CN¥31.09
About

ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products. It provides anti-infective drugs, anti-allergic drugs, smoking cessation drugs, pediatric drugs, respiratory system drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, nephropathy drugs, anti-depressant… Read more